Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?

被引：0
|
作者：
Vitale, Pasquale [1 ]
De Falco, Vincenzo [1 ]
Addeo, Raffaele [1 ,2 ]
机构：
[1] Hosp Frattamaggiore, Oncol Operat Unit, Frattamaggiore, Italy
[2] ASLNA2NORD, San Giovanni Dio Hosp, Oncol Operat Unit, Via D Pirozzi 62, I-80027 Frattamaggiore, NA, Italy
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2024年 / 24卷 / 07期
关键词：
Recurrent/metastatic head and neck cancer; cetuximab; PD-L1; pembrolizumab; chemotherapy; combined positive score; SQUAMOUS-CELL CARCINOMA; CHEMOTHERAPY PLUS CETUXIMAB; RECURRENT; PEMBROLIZUMAB; KEYNOTE-048;
D O I：
10.1080/14737140.2024.2354772
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：481 / 484
页数：4
相关论文
共 50 条
  • [21] DOCETAXEL PLUS CISPLATIN AS FIRST-LINE CHEMOTHERAPY IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER
    Ohhara, Y.
    Nishimura, N.
    Nara, E.
    Nakano, K.
    Ueda, K.
    Sakajiri, S.
    Mishima, Y.
    Yokoyama, M.
    Terui, Y.
    Takahashi, S.
    Hatake, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 125 - 125
  • [22] Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
    Hitt, R.
    Irigoyen, A.
    Cortes-Funes, H.
    Grau, J. J.
    Garcia-Saenz, J. A.
    Cruz-Hernandez, J. J.
    ANNALS OF ONCOLOGY, 2012, 23 (04) : 1016 - 1022
  • [23] Outcomes of Chemotherapy plus Cetuximab as First-line Treatment in Patients with Metastatic, Recurrent, Unresectable Head and Neck Cancers: Real-life Data
    Yazilitas, Dogan
    Sahinli, Hayriye
    Saylam, Guleser
    Imamoglu, Goksen Inanc
    Korkmaz, Mehmet Hakan
    Bayir, Omer
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2023, 33 (04): : 469 - 473
  • [24] An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer
    Cavalieri, Stefano
    Serafini, Mara Serena
    Carenzo, Andrea
    Canevari, Silvana
    Lenoci, Deborah
    Pistore, Federico
    Miceli, Rosalba
    Vecchio, Stefania
    Ferrari, Daris
    Moro, Cecilia
    Sponghini, Andrea
    Caldara, Alessia
    Rocca, Maria Cossu
    Secondino, Simona
    Moretti, Gabriella
    Denaro, Nerina
    Caponigro, Francesco
    Vaccher, Emanuela
    Rinaldi, Gaetana
    Ferrau, Francesco
    Bossi, Paolo
    Licitra, Lisa
    De Cecco, Loris
    CELLS, 2022, 11 (19)
  • [25] Safety and effectiveness in daily clinical practice of the Cetuximab-Docetaxel-Cisplatin protocol in recurrent head and neck cancer and/or first-line in metastatic disease
    Felipe Sanchez-Cousido, Luis
    Rodriguez Sanchez, Angel
    Lopez-Flores, Mariana
    Lopez-Gonzalez, Ana
    Castanon-Lopez, Carmen
    Lanz Lozano, Amaya
    Rojas Piedra, Mariam
    Tavara Silva, Blanca
    Garcia-Palomo, Andres
    ORAL ONCOLOGY, 2021, 118
  • [26] Cost-effectiveness of Molecular Profile Patient Selection for First-line Treatment of Recurrent/Metastatic Head and Neck Cancer
    Rognoni, Carla
    Quaglini, Silvana
    Vermorken, Jan Baptist
    De Cecco, Loris
    Licitra, Lisa
    Bossi, Paolo
    CLINICAL THERAPEUTICS, 2019, 41 (12) : 2517 - 2528
  • [27] Erbitux® (Cetuximab): New standard in the first line therapy of recurrent and/or metastatic head neck tumours
    不详
    ONKOLOGIE, 2009, 32 (11): : 691 - 691
  • [28] How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?
    Lindsay, Colin R.
    Roxburgh, Patricia
    Graham, Janet
    FUTURE ONCOLOGY, 2013, 9 (06) : 825 - 829
  • [29] Paclitaxel plus cetuximab for the treatment of recurrent and/or metastatic head and neck cancer after first-line checkpoint inhibitor failure: Primary analysis from the pace ace trial
    Fuereder, T.
    Klinghammer, K.
    Hahn, D. A.
    Gruenberger, B.
    Melchardt, T.
    Greil, R.
    Kocher, F.
    Gamerith, G.
    Wagner, C.
    Berchtold, L.
    Burian, M.
    Strobl, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S629 - S629
  • [30] Approval Summary: Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil for the First-Line Treatment of Patients With Recurrent Locoregional or Metastatic Squamous Cell Head and Neck Cancer
    Cohen, Martin H.
    Chen, Huanyu
    Shord, Stacy
    Fuchs, Chana
    He, Kun
    Zhao, Hong
    Sickafuse, Sharon
    Keegan, Patricia
    Pazdur, Richard
    ONCOLOGIST, 2013, 18 (04): : 460 - 466
12345